Skip to main content
TipRanks
Go Ultimate75% OFF

Petmed Express (PQM) AI Stock Analysis

3 Followers
DE:PQM

Petmed Express

(Frankfurt:PQM)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low LeverageMinimal debt gives PetMed Express greater financial flexibility while it restructures operations and pursues growth initiatives. Low leverage reduces interest and solvency pressure, allowing more of any future operating improvement to support investment, liquidity, and recovery efforts.
Negative Factors
Revenue ContractionDeclining prescription revenue weakens the company’s core demand base and makes fixed operating costs harder to absorb. Continued softness would limit the benefits of cost actions, reduce scale across fulfillment and marketing, and delay a durable return to revenue growth.

Petmed Express (PQM) vs. iShares MSCI Germany ETF (EWG)

-75%-50%-25%0%25%50%75%100%125%DE:PQM-50.50%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 19.96M
Dividend Yield
―
Average Volume (3M)
962
Price to Earnings (P/E)
-0.7
Beta (1Y)
1.38
Revenue Growth
-22.06%
EPS Growth
53.31%
Country
Germany
Employees
189
Sector
Healthcare
Sector Strength
51
Industry
Specialty Retail

Petmed Express Business Overview & Revenue Model

Company Description

PetMed Express, Inc., through its various subsidiaries, operates as a prominent pet pharmacy across the United States. The company provides a comprehensive range of both prescribed and over-the-counter animal medications, health-related items, and ot...

Petmed Express Earnings Call Summary

Earnings Call Date:Aug 13, 2026(Q1-2027)|% Change Since:-54.80%|Next Earnings Date:Jul 28, 2025
Earnings Call SentimentPositive

The call presents a cautiously optimistic tone: management reported substantial progress on cost reductions, major technology and operational upgrades (SAP rollout, call center, fraud prevention), improved customer acquisition efficiency (70k new customers; CAC down 15%), higher recurring revenue mix (61.5% of sales), strategic white-label partnership with Rural King, and a sale-leaseback to unlock $37M of real estate value. However, notable challenges remain, including a 19.9% year-over-year revenue decline driven by weaker prescription sales, lower gross profit, an increased adjusted EBITDA loss, and an outstanding unsolicited acquisition proposal. On balance, the operational and financial improvements and strategic initiatives meaningfully outweigh the current headwinds, but execution risk on pending transactions and sustained revenue recovery remain important considerations.

Positive Updates

Net Loss Narrowed Substantially
Net loss improved to $6.1 million (−$0.28 per diluted share) in Q1 FY27 compared to a net loss of $34.2 million (−$1.65 per diluted share) in the prior-year period, an ~82.1% reduction in the year-over-year net loss magnitude driven primarily by absence of last year's goodwill/trade name impairment and lower operating costs.

Negative Updates

Significant Year-over-Year Revenue Decline
Net sales declined 19.9% year-over-year to $41.0 million (from $51.2 million), primarily driven by continued softness in prescription medication sales.

Company Guidance

Management provided no formal numeric forward guidance but outlined a clear, metric‑driven path to sustainable profitability: they expect benefits from recent tech and operations investments (SAP ERP rolled out in May, new call‑center platform launched in June, Q4 fraud system) and a new freight agreement that can shave up to 2 days off West Coast deliveries to improve retention, while expanding white‑label partnerships (Rural King launched in July across >150 stores in 17 states). Key Q1 metrics they cited as the baseline for this plan include net sales of $41.0M (down 19.9% YoY from $51.2M) — the third consecutive quarter above $40M — gross profit $11.3M (27.6% margin), G&A $11.2M (‑13.5% YoY), advertising $4.2M (‑30.2% YoY), depreciation & amortization $2.1M, net loss $6.1M ($0.28/share) vs a loss of $34.2M ($1.65) a year ago, adjusted EBITDA loss $3.4M, cash $13.1M and no debt, recurring net sales 61.5% of gross (vs 57.6% a year ago), ~70k new customers acquired in Q1 with CAC down 15% to $60 (from $71), and an expected $37M sale‑leaseback of HQ/DC to close in ~120 days under a 10‑year lease to bolster financial flexibility.

Petmed Express Risk Analysis

Petmed Express disclosed 36 risk factors in its most recent earnings report. Petmed Express reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Petmed Express Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:PQM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CHWYCHWY64Neutral$8.69B32.9462.13%―5.86%81.66%
TSCOTSCO59Neutral$19.68B20.3437.64%2.50%3.53%-10.44%
WOOFWOOF58Neutral$790.52M24.802.58%―-1.32%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BARKBARK47Neutral$83.77M-3.38-32.36%―-22.21%31.35%
BQBQ41Neutral$3.15M-1.07-2.77%―-8.84%8.50%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:PQMTSCOCHWYBQBARKWOOFDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:PQM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:PQMPetmed Express0.74-0.83-52.76%
TSCOTractor Supply Company37.95-14.32-27.40%
CHWYChewy Inc21.62-12.90-37.37%
BQBoqii Holding Limited0.40-1.52-79.17%
BARKBARK Inc Class A9.40-4.80-33.80%
WOOFPetco Health And Wellness Company Inc2.76-0.11-3.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.